Tearlab Corp Receives a Hold from Roth Capital

By Austin Angelo

Roth Capital analyst Chris Lewis reiterated a Hold rating on Tearlab Corp (NASDAQ: TEAR) today and set a price target of $4.50. The company’s shares opened today at $4.90.

According to TipRanks.com, Lewis is a 4-star analyst with an average return of 6.4% and a 53.6% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Cogentix Medical Inc, Trinity Biotech Plc, and Lemaitre Vascular.

Tearlab Corp has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.

Based on Tearlab Corp’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $7.22 million and GAAP net loss of $3.98 million. In comparison, last year the company earned revenue of $6.79 million and had a GAAP net loss of $8.93 million.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TEAR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TearLab Corp. engages in the development and marketing of lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by testing disease markers in tears at the point-of-care. It also intends to measure the osmolarity of human tears to aid in the diagnosis of dry eye disease in patients suspected of having dry eye disease. The company was founded by Benjamin D. Sullivan in 1996 and is headquartered in San Diego, CA.